2025 · 1st Quarter (Jan 1 - Mar 31)

ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION

Filed by THE WASHINGTON TAX & PUBLIC POLICY GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 8, 2025
Income: $450,000.00
Expenses: Not reported
Registrant: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Client: ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION
Filing UUID: ce700d49-b8a6-4f42-be0c-8ed93495b9e1
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

TAX · Taxation/Internal Revenue Code

Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 951A, 250, 163(j), 168, 174 and 41. (H.R.1990, H.R. 574, H.R. 1062, S. 187). Issues related to interest deductibility. (H.R. 1347, S. 559)

Literal federal measure citations: H.R.1990, H.R. 574, H.R. 1062, S. 187, H.R. 1347, S. 559

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.